The patent EP3340989B1 was granted on Aug 16, 2023 by Novartis The patent is currently Granted And Under Opposition.
Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.
The table below shows the patents of Novartis that have been opposed by other companies.
The dossier documents provide a comprehensive record of the patent’s prosecution history, including filings, correspondence, and decisions made by patent offices. These documents are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination. It also includes the oppositions documents filed against the patent.
Date
Description
Get instant alerts for new documents